The Clinical Efficacy and Safety of Gumiganghwal-Tang in Knee Osteoarthritis: A Phase II Randomized Double Blind Placebo Controlled Study
Table 2
Demographic data and baseline characteristics.
Characteristics
GMGHT group (n= 70)
Placebo group (n= 73)
p value
Sex (female), n (%)
67 (95.7)
62 (84.9)
0.05
Age
58.5 (8.7)
59.7 (7.5)
0.41
Height (m)
1.57 (0.06)
1.57 (0.07)
0.77
Body weight
59.1 (6.7)
62.3 (9.3)
0.02
BMI (kg/m2)
23.9 (2.2)
25.2 (4.2)
0.02
Duration of symptomatic OA (months)
51.7 (54.3)
61.4 (63.3)
0.33
Radiographic findings (Kellgren and Lawrence X-ray grade )
Grade 2, n (%)
45 (64.3)
42 (57.5)
0.43
Grade 3, n (%)
20 (28.6)
28 (38.4)
Grade 4, n (%)
5 (7.1)
3 (4.1)
Patient’s global assessment (0-100 VAS)
65.1 (17.5)
69.2 (13.0)
0.13
Patient’s pain assessment (0-100 VAS)
68.4 (11.5)
71.0 (13.6)
0.22
Physician’s global assessment (0-100 VAS)
65.7 (11.8)
68.1 (13.4)
0.28
WOMAC score
Pain
11.1 (2.3)
11.3 (3.0)
0.70
Stiffness
4.7 (1.3)
4.3 (1.4)
0.17
Function
39.6 (10.0)
40.5 (9.6)
0.55
Total
55.4 (12.7)
56.2 (12.9)
0.70
Values are presented as numbers (%) or mean (SD) unless otherwise stated. BMI: body mass index, GMGHT: Gumiganghwal-tang, OA: osteoarthritis, SD: standard deviation, VAS: visual analog scale, WOMAC: the Western Ontario and McMaster Universities Arthritis Index.